- Home
- PRPH vs MTVA Comparison
PRPH vs MTVA Comparison
Compare PRPH & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- MTVA
- Stock Information
- Founded
- PRPH 1989
- MTVA 2014
- Country
- PRPH United States
- MTVA United States
- Employees
- PRPH N/A
- MTVA N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- PRPH Health Care
- MTVA
- Exchange
- PRPH Nasdaq
- MTVA NYSE
- Market Cap
- PRPH 10.7M
- MTVA 12.5M
- IPO Year
- PRPH 1997
- MTVA N/A
- Fundamental
- Price
- PRPH $0.43
- MTVA $1.51
- Analyst Decision
- PRPH
- MTVA Strong Buy
- Analyst Count
- PRPH 0
- MTVA 1
- Target Price
- PRPH N/A
- MTVA $12.00
- AVG Volume (30 Days)
- PRPH 27.1M
- MTVA 27.0K
- Earning Date
- PRPH 03-18-2025
- MTVA 05-08-2025
- Dividend Yield
- PRPH N/A
- MTVA N/A
- EPS Growth
- PRPH N/A
- MTVA N/A
- EPS
- PRPH N/A
- MTVA N/A
- Revenue
- PRPH $12,753,000.00
- MTVA N/A
- Revenue This Year
- PRPH $36.93
- MTVA N/A
- Revenue Next Year
- PRPH $132.05
- MTVA N/A
- P/E Ratio
- PRPH N/A
- MTVA N/A
- Revenue Growth
- PRPH N/A
- MTVA N/A
- 52 Week Low
- PRPH $0.22
- MTVA $1.29
- 52 Week High
- PRPH $7.48
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- PRPH 48.83
- MTVA N/A
- Support Level
- PRPH $0.31
- MTVA N/A
- Resistance Level
- PRPH $0.46
- MTVA N/A
- Average True Range (ATR)
- PRPH 0.07
- MTVA 0.00
- MACD
- PRPH 0.00
- MTVA 0.00
- Stochastic Oscillator
- PRPH 46.28
- MTVA 0.00
Stock Price Comparison Chart: PRPH vs MTVA
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.